Despite the rapid growth of imaging and treatment options in interventional oncology, one area that has been poorly understood and overlooked by the interventional community is the role of the tumour microenvironment and its impact on the delivery of therapeutic agents.
Vascular Solutions has announced the US market launch of its Gel-Bead embolization spheres for the treatment of hypervascular tumours
DFINE has announced the publication of a multicentre study in the July/August issue of Pain Physician Journal, the official peer-reviewed publication of the American Society of Interventional Pain Physicians (ASIPP). The study followed patients at five leading academic centres and found a significant decrease (p <0.01) in pain scores after targeted radiofrequency ablation (t-RFA) with the Star tumour ablation system
Overcoming a significant roadblock to predictable ablation of soft tissue, Covidien has unveiled an advanced ablation system that offers physicians predictable results regardless of the target location or tissue type. The Emprint ablation system with Thermosphere technology is designed to precisely heat and destroy diseased soft tissue (including liver, lung and kidney), and non-resectable liver tumours.
The evidence supporting the use of transarterial chemoembolization (TACE) and Yttrium-90 transarterial radioembolization (TARE) to treat primary and secondary liver malignancies for palliation, survival benefit, bridging or downstaging to liver transplant or hepatic resection is expanding, both with respect to volume and quality. As a result, the number of these procedures being performed is on the rise. However, unintended non target delivery of TACE or TARE agents into any of the various hepaticoentric arteries that course from an intrahepatic artery to implant into an extra hepatic organ such as the stomach or small intestine can result in serious complications, especially gastrointestinal ulcerations, particularly with Y-90 microspheres. In the 1990s, the reported rates of such ulcerations was in the range of 15%. Subsequently, with standard lobar or sublobar dose delivery, rigorous coil embolization of all identified hepaticoentric arteries, and liberal use of core beam CT, the reported rate of gastrointestinal ulceration from TARE generally reduced to the range of 2–5%. Thorough coil embolic protection is both technically challenging and time consuming, and occasionally cannot be accomplished. An unintended consequence of coil embolization of the gastroduodenal artery is the subsequent angiographic appearance of “new” hepaticoentric arteries such as the supraduodenal artery that occur in 35% of patients. These are difficult, and at times impossible to catheterise and to place microcoils in.
Boston Scientific Corporation closed on its previously announced agreement to purchase the Interventional business of Bayer AG. The acquisition enhances the ability of Boston Scientific to offer physicians and healthcare systems a more complete portfolio of solutions to treat challenging vascular conditions.
CeloNova has announced US FDA 510(k) clearance expanding the indication for their Oncozene and Embozene microsphere products to now include the embolization of hepatocellular carcinoma.
Kona Medical has announced the initiation of the WAVE IV, randomised, sham-controlled, double-blinded, clinical trial of its Surround Sound Hypertension Therapy System. The trial will treat 132 patients at sites in Europe, New Zealand, Australia, and South America.
Covidien has announced that it has acquired Sapheon, a privately-held developer of venous disease treatments. Financial terms of the transaction were not disclosed
The findings from a report commissioned by the Canadian Interventional Radiology Association (CIRA) and carried out by the Millennium Research Group (MRG) indicate that Canada lags behind other industrialised countries in the G7 such as Europe, USA and Japan in the adoption of interventional radiology treatment. Canada received formal recognition as a clinical subspecialty for interventional radiology in 2013.
Women could be at higher risk for adverse outcomes than men, but overall they have similar procedural success compared with men despite higher complications rates, data from a study published in Journal of the American College of Cardiology in June suggests
ArtVentive Medical Group has announced excellent clinical results in conjunction with expanded enrolment in the ArtVentive Endoluminal Occlusion System, or ArtVentive EOS device, OCCLUDE I post-market surveillance study.
New technology in the form of a magnetically-assisted remote-controlled catheter (MARC) which could allow physicians to see and assess brain tissue more clearly while treating a stroke may hold promise, according to study authors who released their findings at the Society of NeuroInterventional Surgery (SNIS) 11th Annual Meeting in Colorado Springs, USA
A small study conducted in Japan, published in CardioVascular and Interventional Radiology in July 2014, demonstrates that transcatheter arterial embolization is feasible and that it rapidly relieves pain associated with knee osteoarthritis and restores knee function.
The sobering results from SYMPLICITY-HTN 3 trial,1 which found that Medtronic’s Symplicity system was not associated with significant reductions in blood pressure compared with a sham procedure, have left some casual observers sceptical about the promise of renal denervation as a means to manage resistant hypertension
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos